The role of Budesonide-MMX in active ulcerative colitis

References

• Truelove SC, Witts LJ. Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. BMJ 1954;2:375-8
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1(7866):1067-70
   PubMed Web of Science ®Google Scholar
• Goldstein F. Reflections on the treatment of CD, the NCCDS report, and on randomized clinical trials. J Clin Gastroenterol 1980;2:115-17
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, et al. European Cooperative CD Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study. Gastroenterology 2001;121:255-60
   PubMed Web of Science ®Google Scholar
• Ryrfeldt A, Edsbacker S, Pauwels R. Kinetics of the epimeric glucocorticoid budesonide. Clin Pharmacol Ther 1984;35:525-30
   PubMed Web of Science ®Google Scholar
• Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995;23:137-42
   PubMed Web of Science ®Google Scholar
• Edsbacker S, Andersson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos 1987;15:403-11
   PubMed Web of Science ®Google Scholar
• Spencer CM, McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995;50:854-72
   PubMed Web of Science ®Google Scholar
• McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active CD in adults. Drugs 2002;62:2263-82
   PubMed Web of Science ®Google Scholar
• Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48:571-7
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 2005;57:303-16
   PubMed Web of Science ®Google Scholar
• Cui N, Friend DR, Fedorak RN. A budesonide prodrug accelerates treatment of colitis in rats. Gut 1994;35:1439-46
   PubMed Web of Science ®Google Scholar
• Nolen H 3rd, Fedorak RN, Friend DR. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. J Pharm Sci 1995;84:677-81
   PubMed Web of Science ®Google Scholar
• Budesonide enema in distal ulcerative colitis: a randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991;26:1225-30
   PubMed Web of Science ®Google Scholar
• Lémann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:557-62
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn´s disease. N Engl J Med 1994;331:836-41
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active CD. N Engl J Med 1994;331:842-5
   PubMed Web of Science ®Google Scholar
• Campieri M, Ferguson A, Doe W, Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active CD. Gut 1997;41:209-14
   PubMed Web of Science ®Google Scholar
• Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in CD. Cochrane Database Syst Rev 2008(3):CD000296
   Google Scholar
• Sandborn WJ, Löfberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with CD in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-7
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in CD. Cochrane Database Syst Rev 2009(1):CD002913
   Google Scholar
• Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent CD. Inflamm Bowel Dis 2009;15(3):375-82
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent CD. Clin Gastroenterol Hepatol 2003;1:122-8
   PubMed Web of Science ®Google Scholar
• Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in CD. The IOIBD Budesonide Study Group. Gastroenterology 1999;116:294-300
   PubMed Web of Science ®Google Scholar
• Ewe K, Böttger T, Buhr HJ, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of CD: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol 1999;11:277-82
   PubMed Web of Science ®Google Scholar
• Keller R, Stoll R, Foerster EC, et al. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther 1997;11:1047-52
   PubMed Web of Science ®Google Scholar
• Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal CD. A placebo controlled one year study. Gut 1996;39:82-6
   PubMed Web of Science ®Google Scholar
• Gross V, Bunganic I, Belousova EA, et al. 3 g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2011;5:129-38
   PubMed Web of Science ®Google Scholar
• Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006;61:31-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007;26:205-15
   PubMed Web of Science ®Google Scholar
• Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003;17(3):395-402
   PubMed Web of Science ®Google Scholar
• Hebden JM, Blackshaw PE, Perkins AC, et al. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000;14:155-61
   PubMed Web of Science ®Google Scholar
• Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11:421-7
   PubMed Web of Science ®Google Scholar
• D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006;24:1087-97
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102
   PubMed Web of Science ®Google Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Kovács A, Vergauwe P, et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010;4:153-60
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6
   PubMed Web of Science ®Google Scholar
• Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986;90(5 Pt 1):1121-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143:1218-26
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987;32(12 Suppl):64S-6S
   Web of Science ®Google Scholar
• Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106:601-16
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Andreas Sturm A, et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn Colitis 2012;6:991-1030
   PubMed Web of Science ®Google Scholar